HOME2020-06-08T11:37:23+01:00

The PD-MitoQUANT Project

Today, more than one million people live with Parkinson’s in Europe and this number is forecast to double by 2030. New, more effective treatments are urgently needed – but researchers and companies developing new drugs need to know more about how mitochondrial dysfunction is involved in disease progression and better models are needed for drug discovery and development.

PD-MitoQUANT is an Innovative Medicines Initiative (IMI) project that brings together academic experts, SMEs, pharmaceutical companies from the European Federation of Pharmaceutical Industries and Associations (EFPIA) and patient advocacy organisation Parkinson’s UK to:

  • improve our understanding of mitochondrial dysfunction in Parkinson’s,

  • identify and validate molecular drivers and mechanisms in Parkinson’s, and

  • discover innovative therapeutic targets that can be further progressed by the EFPIA partners in the future.

Latest News

Parkinson’s UK hosts Research Conference 2020

July 6th, 2020|

Our partner Parkinson's UK is hosting an online research conference on September 24th and 25th, 2020. The 2020 theme is "Accelerating research and improving care". This is a CPD-accredited entirely online meeting held over two days. Keynote lectures will be delivered live from around the world. Symposia will be available [...]

RCSI team publishes PD-MitoQUANT study in Journal of Neuroscience

June 15th, 2020|

The RCSI, Royal College of Surgeons in Ireland team comprised of  Orla Watters, Niamh M. C. Connolly, Hans-Georg König, Heiko Duessmann and Jochen Prehn published a PD-MitoQUANT-acknowledged paper in the Journal of Neuroscience. The study entitled: AMPK preferentially depresses retrograde transport of axonal mitochondria during localised nutrient deprivation appeared online on [...]

New PD-MitoQUANT study published by CNRS researchers

May 25th, 2020|

Congratulations to Maya Bendifallah, Virginie Redeker, Elodie Monsellier, Luc Bousset*, Tracy Bellande, and Ronald Melki* for the publication of their recent study entitled: Interaction of the chaperones alpha B-crystallin and CHIP with fibrillar alpha-synuclein: Effects on internalization by cells and identification of interacting interfaces. The paper appeared in the journal [...]

Read more